scan the qr code here

Genessense, C/o. MedGenome Labs Ltd., 3rd Floor, Narayana Nethralaya BuildingNarayana Nethralaya City, #258/A, Bommasandra, Hosur Road, Bangalore-560 099

Phone: 1800 103 7590

Email: [email protected]

Website: www.genessense.com

To know more

about CUREGEN,

scan the QR code here

YO U R P E R S O N A L I Z E D D R U G

R E S P O N S E R E P ORT

Your personalized drug response report

NAME

GENDER

KIT ID

Saliva / blood

SAMPLE TYPE

No two people are the same. Our genetic makeup makes us all unique.

We have assessed your response to 45+ drugs/drug classes covered across

10 disease categories. across a range of diseases. These results will let you

know if you metabolize these drugs differently than average.

The report will tell you if the drug has normal, decreased, increased or

no function in your body.

Please Note: Your health care provider also considers other factors such as your

age, lifestyle, other medications you are taking and your overall health when

choosing the right treatment for you.

TRUE WELLBEING THROUGH

PERSONALIZED MEDICINE

18 Covering genesAssess your response to 45+ drugs/drug classes

SUMMARY OF RESULTS

DISEASE / DRUG CLASS DRUGS FUNCTION OF GENE PRODUCT GENES

Normal Decreased Increased No function

CARDIOVASCULAR

DISEASES

Warfarin VKRORC1

Clopidogrel

Fluvastatin#

CYP2C9

CYP4F2

CYP2C19

SLCO1B1

CYP2D6

RYR1

RYR1

CodeinePAIN/ANTIEMETICS

ANESTHESIA Anesthetic

Agents

Succinylcholine

CYP2C19

CYP2B6

VoriconazoleINFECTIOUS

DISEASES / HIV

NEUROLOGY

Efavirenz

Phenytoin CYP2C9

SUMMARY OF RESULTS

# CPIC recommendation for Simvastatin.

Red slider indicates variant detected in only one allele.

DISEASE / DRUG CLASS DRUGS FUNCTION OF GENE PRODUCT GENES

Normal Decreased Increased

ONCOLOGY Fluoropyrimidines

(5-FU, capecitabine)

Tamoxifen

Irinotecan

Interferon

Thiopurines

(azathioprine,

mercaptopurine,

thioguanine)

DPYD

CYP2D6

UGT1A1

IFNL3

NUDT15

TPMT

CYP2C19

CYP2D6

CYP2C19

Selective

Serotonin,

Reupdate

Inhibitors

(citalopram,

escitalopram,

fluvoxamine,

paroxetine,

sertraline)

Tricyclic

Antidepressants

(amitriptyline,

clomipramine,

desipramine,

doxepin,

imipramine,

nortriptyline,

trimipramine

PSYCHIATRY

CYP3A5

G6PD

TacrolimusTRANSPLANT

OTHERS Rasburicase

No function

CARDIOVASCULAR DISEASES

RESULT INTERPRETATION

What is CYP4F2 and its relevance?

This gene encodes a member of the cytochrome P450 superfamily of enzymes.

This gene is part of a cluster of cytochrome P450 genes on chromosome 19.

The cytochrome P450 proteins are monooxygenases which catalyze many

reactions involved in drug metabolism and synthesis of cholesterol, steroids

and other lipids and involved in the metabolism of various endogenous

substrates, including fatty acids, eicosanoids, and vitamins. The enzyme starts

the process of inactivating and degrading leukotriene B4, a potent mediator

of inflammation.

How does the variation above affect your drug response?

Warfarin is an anticoagulant used to treat blocks in blood vessels. Studies have

also demonstrated that carriers of the CYP4F2*3 variant allele have a reduced

capacity to metabolize vitamin K, and therefore, a higher warfarin dose was

required to elicit the same anticoagulant response. Individuals with the CT

genotype who are treated with warfarin may require a lower dose as compared

to patients with the TT genotype[8, 9]. Other genetic and clinical factors may

also influence a patient’s required warfarin dose. All changes in medications

must be done under clinical supervision.

GENE DRUGCPIC ALLELE

NAME (rsID)

REFERENCE

GENOTYPE

VARIANT

GENOTYPE

YOUR

GENOTYPE

CHROMOSOME

POSITION (hg19)

MARKER ID

(dbSNP ID)

CYP4F2 Warfarin *3 C T C T chr19:15990431 rs2108622

CYP2C19 Clopidogrel *17 C T C T chr10:96521657 rs12248560


What is CYP2C19 and its relevance?

The CYP2C19 gene is a member of the cytochrome P450 gene family and

provides instructions for making an enzyme that is found primarily in liver cells

in a cell structure called the endoplasmic reticulum, which is involved in protein

processing and transport. The CYP2C19 enzyme plays a role in the processing

or metabolizing of a drug called clopidogrel (also known as Plavix) which

prevents blood cells called platelets from sticking together (aggregating) and

forming blood clots. The CYP2C19 enzyme converts clopidogrel to its active form,

which is necessary for the drug to function in the body. The active drug then

stops (inhibits) a receptor protein known as P2RY12 that is found on the surface

of platelets. During clot formation, the P2RY12 receptor protein helps platelets

cluster together to form a clot to seal off damaged blood vessels and prevent

blood loss.


Clopidogrel is an anticoagulant that prevents platelet aggregation and

therefore, used to treat blocks in blood vessels. Individuals with CT genotype

(CYP2C19*17; rs12248560), carrying one functional allele plus one increased

function allele, may have increased activation of clopidogrel, resulting in an

increased risk of bleeding with clopidogrel and a decreased, but not absent,

risk for adverse cardiovascular events as compared to patients with a CC

genotype. CPIC recommends label recommended dosage and administration.

Other genetic and clinical factors may also influence a patient’s risk for

secondary cardiovascular events and response to clopidogrel[10].

INFECTIOUS DISEASES / HIV














blood loss.


Voriconazole is a triazole antifungal agent that inhibits ergosterol synthesis

by inhibiting lanosterol 14a-demethylase. Due to the interpatient variability

in voriconazole pharmacokinetics and to avoid the toxicity associated with

elevated concentrations and therapeutic failures with low concentrations,

voriconazole therapeutic drug monitoring (TDM) has been recommended.

Individuals with CT genotype (CYP2C19*17; rs12248560), carrying one functional

allele plus one increased function allele, are rapid metabolizers of

voriconazole. These individuals have increased metabolism of voriconazole

and are likely to have undetectable levels of the drug or lack of response as

compared to individuals with two functional alleles. CPIC recommends the

use of an alternative agent that is not dependent on CYP2C19 metabolism

as primary therapy in lieu of voriconazole. Such agents include isavuconazole,

liposomal amphotericin B, and posaconazole. For pediatric patients, CPIC

recommends initiating therapy with recommended standard case dosing.

Use therapeutic dose monitoring to titrate dose to therapeutic trough

concentrations[11]. Other genetic and clinical factors may also influence

voriconazole metabolism, response and adverse effects.


NAME (rsID)

REFERENCE

GENOTYPE

VARIANT

GENOTYPE

YOUR

GENOTYPE

CHROMOSOME

POSITION (hg19)

MARKER ID

(dbSNP ID)

CYP2C19 Voriconazole *17 C T C T chr10:96521657 rs12248560

ONCOLOGY


What is IFNL3 and its relevance?

IFNL3 encodes a cytokine distantly related to type I interferons and the IL-10

family. IFNL3, interleukin 28A (IL28A), and interleukin 29 (IL29) are three

closely related cytokine genes that form a cytokine gene cluster on a

chromosomal region mapped to 19q13. Cytokine has antiviral, antitumor and

immunomodulatory activities and plays a critical role in the antiviral host

defense, predominantly in the epithelial tissues. All three cytokines have

been shown to interact with a heterodimeric class II cytokine receptor that

consists of interleukin 10 receptor, beta (IL10RB) and interleukin 28 receptor,

alpha (IL28RA). Expression of the cytokines encoded by the three genes can be

induced by viral infection.


Interferons are proteins produced by tumor cells or host cells that are infected

with viruses, bacteria and other unknown nucleic acids. Interferons also activate

other cells that serve as part of the immune system and destroy invading

pathogens. Individuals with CT genotype and Hepatitis C genotype 1 may have

decreased response (typically assayed as sustained virological response, SVR)

when administered peginterferon alpha 2a and/or 2b in combination with

ribavirin as compared to patients with the CC genotype[12]. CPIC recommends

to consider implications before initiating PEG-IFNα and RBV-containing

regimens. Other genetic and clinical factors may also influence a patient’s

response. All changes in medications must be done under clinical supervision.


NAME (rsID)

REFERENCE

GENOTYPE

VARIANT

GENOTYPE

YOUR

GENOTYPE

CHROMOSOME

POSITION (hg19)

MARKER ID

(dbSNP ID)

IFNL3 Interferon rs12979860 C T C T chr19:39738787 rs12979860

PSYCHIATRY














blood loss.


Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options

for major depressive and anxiety disorders. The more common adverse

effects induced by this drug class include central nervous system effects

(e.g., insomnia, headache), gastrointestinal dysfunction, and sexual dysfunction;

however, the incidence of side effect occurrence differs with each drug.

CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby

affecting drug efficacy and safety. Citalopram is a racemic mixture of R- and

S-enantiomers, with the pharmacologically active S-enantiomer marketed

as escitalopram. Citalopram and escitalopram are extensively metabolized

by CYP2C19 to compounds that confer less serotonin reuptake inhibition.

Because citalopram and escitalopram are extensively catalyzed by CYP2C19,

variations in CYP2C19 activity may result in altered drug exposure.


NAME (rsID)

REFERENCE

GENOTYPE

VARIANT

GENOTYPE

YOUR

GENOTYPE

CHROMOSOME

POSITION (hg19)

MARKER ID

(dbSNP ID)

CYP2C19

Citalopram

or

Escitalopram

*17 C T C T chr10:96521657 rs12248560

CYP2C19 Amitriptyline *17 C T C T chr10:96521657 rs12248560


allele plus one increased function allele are rapid metabolizers of citalopram

or escitalopram. These individuals may have increased metabolism when

compared to normal metabolizers and lower plasma concentrations will

increase probability of pharmacotherapy failure. CPIC recommends the

use of an alternative drug not predominantly metabolized by CYP2C19.

Other genetic and clinical factors may also influence citalopram or

escitalopram metabolism, response and adverse effects[13].

Tricyclic antidepressants (TCAs) are mixed serotonin and norepinephrine

reuptake inhibitors used to treat several disease states including depression,

obsessive-compulsive disorder, and neuropathic pain in addition to

migraine prophylaxis. Both amitriptyline and nortriptyline are used as

representative TCAs.


allele plus one increased function allele are rapid metabolizers, and

therefore, have an increased metabolism of tertiary amines compared to

normal metabolizers. CPIC recommends avoiding tertiary amine use due

to potential for sub-optimal response. Consider an alternative drug not

metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include

the secondary amines nortriptyline and desipramine. If a tertiary amine is

warranted, utilise therapeutic drug monitoring to guide dose adjustments.

Other genetic and clinical factors may also influence a patient’s response

to amitriptyline[14].

All changes in medications must be done under clinical supervision.

TRANSPLANT


What is CYP3A5 and its relevance?

Protein encoded by CYP3A5 metabolizes drugs as well as the steroid hormones

testosterone and progesterone.

Variations in the CYP3A5 gene can lead to a difference in response to certain

class of drugs called immunosuppressants.


Tacrolimus is the mainstay immunosuppressant drug used after solid organ

and hematopoietic stem cell transplantation. Individuals who express CYP3A5

CC (rs776746) genotype are poor metabolizers, with two non-functional allele.

Patients with the CC (*3/*3) genotype and recipients of kidney or hematopoietic

stem cell transplant, being poor metabolizers, do not metabolize, CYP3A

substrates such as tacrolimus as rapidly as patients with CT (*1/*3 ) or TT (*1/*1)

genotypes and therefore the standard dose of tacrolimus is sufficient to

prevent graft rejection. CPIC recommends initiating therapy with standard

recommended dose and use therapeutic drug monitoring to guide dose

adjustments. Other genetic and clinical factors may also influence a patient’s

tacrolimus dose requirements[15].


NAME (rsID)

REFERENCE

GENOTYPE

VARIANT

GENOTYPE

YOUR

GENOTYPE

CHROMOSOME

POSITION (hg19)

MARKER ID

(dbSNP ID)

CYP3A5 Tacrolimus *3 C T C C chr7:99270539 rs776746

LIMITATIONS

◼ We have assayed here for only alleles recommended by CPIC for

prescribing action

◼ Onlythealleleswithrelevantvariationshavebeenshowninthereport.

Please refer to the complete list of variants given in appendix 1.

◼ Theremaybeothergenesaffectingdrugresponsewhichhavenotbeen

assayed here

◼ Therecommendationsarebasedonguidelinesandresearchliterature.

This report does not provide a prescription. All changes in medication

must be made only after consulting a trained medical practitioner

USEFULNESS OF THIS REPORT

◼ Youmay share itwith your clinician if you are prescribedwith any of

these drugs

◼ Can be referred pre/post-surgery and management specifically with

reference to use of anesthetics

◼ We have assayed here for only alleles recommended by CPIC for

prescribing action

◼ Thisreportdoesnotprovideanydiagnosisoropinionorrecommendany

cure in any manner

GUIDELINES LEVERAGED FOR ANALYSIS

The Clinical Pharmacogenetics Implementation Consortium (CPIC(7)) is an

international consortium that facilitates clinical implementation of

pharmacogenetic tests through published gene/drug clinical practice

guidelines. CPIC clinical guidelines are endorsed by American Society of

Health System Pharmacists (ASHP) and American Society for Clinical

Pharmacology and Therapeutics (ASCPT).

This Pharmacogenomic profile has been assessed based on recommendations

of the Clinical Pharmacogenetics Implementation Consortium, CPIC, as

updated on March 7, 2019. Gene and disease coverage will change as per

recommendations and research advancements/reports.

Please consult your treating physician before making any changes in your

ongoing medication.

Test Procedure for Drug Response

Saliva DNA Extraction Sequencing /NGS-Analysis

Reporting

DISCLAIMERS

◼ Interpretationofvariantsinthisreportisperformedtothebestknowledgeofthelaboratorybasedontheinformationavailableatthetimeofreporting.

The classification of variants can change over time and we cannot be held responsible for this. Please feel free to contact us in the future to determine

if there have been any changes in the classification of any variants. Re-analysis of variants in previously issued reports considering new evidence is not

routinely performed, but may be available upon request.

◼ ThesensitivityoftheTargetedgenesequencingassaytodetectlargedeletions/duplicationsofmorethan10bporcopynumbervariations(CNV)is70-75%.

The CNVs detected have to be confirmed by alternate method.

◼ Duetoinherenttechnologylimitationsoftheassay,notallbasesofthetargetedregioncanbecoveredbythistest.Accordingly,variantsinregionsof

insufficient coverage may not be identified and/or interpreted. Therefore, it is possible that pathogenic variants are present in one or more of the genes

analyzed but have not been detected. The variants not detected by the assay that was performed may impact the phenotype.

◼ Genes with pseudogenes, paralog genes and genes with low complexity may have decreased sensitivity and specificity of variant detection and

interpretation due to inability of the data and analysis tools to unambiguously determine the origin of the sequence data in such regions.

◼ Inaveryfewcases,genetictestmaynotshowthecorrectresults,e.g.,becauseofthequalityofthesampleprovidedtous.Incasewhereanytestprovided

by us fails for unforeseeable or unknown reasons that cannot be influenced by us in advance, we shall not be responsible for the incomplete, potentially

misleading, or even wrong result of any testing if such could not be recognised by us in advance.

◼ Thisisalaboratorydevelopedtestandthedevelopmentandtheperformancecharacteristicsofthistestwasdeterminedbyus.

◼ Allchangesinmedications,dosingoralternativesmustbedoneuponphysicianconsultation.Changeinmedicationordoseofmedicinewithoutclinical

supervision is not recommended.

REFERENCES

1. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance

Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical

Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5. PubMed PMID:

25741868; PubMed Central PMCID: PMC4544753.

2. Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, Herman GE, Hufnagel SB, Klein TE, Korf BR, McKelvey KD, Ormond KE, Richards CS, Vlangos CN, Watson

M, Martin CL, Miller DT. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy

statement of the American College of Medical Genetics and Genomics. Genet Med.

2017 Feb;19(2):249-255. doi: 10.1038/gim.2016.190. Epub 2016 Nov 17. Erratum in: Genet Med. 2017 Apr;19(4):484. PubMed PMID: 27854360.

3. Freed D. et al., The Sentieon Genomics Tools-A fast and accurate solution to variant calling from next-generation sequence data. BioRxiv:115717, 2017.

4. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010 Mar 1;26(5):589-95. doi: 10.1093/bioinformatics/

btp698. Epub 2010 Jan 15. PubMed PMID: 20080505; PubMed Central PMCID: PMC2828108.

5. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001 Jan

1;29(1):308-11. PubMed PMID: 11125122; PubMed Central PMCID: PMC29783.

6. PharmGKB: https://www.pharmgkb.org/

7. CPIC: https://cpicpgx.org/

8. Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, Lee MT, Gage BF, Kimmel SE, Perera MA, Anderson JL, Pirmohamed M, Klein TE, Limdi NA,

Cavallari LH, Wadelius M. Clinical Pharmacoge- netics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017

Update. Clin Pharmacol Ther. 2017 Sep;102(3):397-404. doi: 10.1002/cpt.668. Epub 2017 Apr 4. PubMed PMID: 28198005; PubMed Central PMCID: PMC5546947.

9. Alvarellos ML, Sangkuhl K, Daneshjou R, Whirl-Carrillo M, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for CYP4F2.

Pharmacogenet Genomics. 2015 Jan;25(1):41-7. doi: 10.1097/FPC.0000000000000100. PMID: 25370453; PMCID: PMC4261059.

10. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR; Clinical Pharmacogenetics Implementation

Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol

Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22. PubMed PMID: 23698643; PubMed Central PMCID: PMC3748366.

11. Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agúndez J, Wingard JR, McLeod HL, Klein TE, Cross SJ, Caudle KE, Walsh TJ. Clinical

Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther. 2017 Jul;102(1):45-51. doi:10.1002/

cpt.583. Epub 2017 Apr 18. Erratum in: Clin Pharmacol Ther. 2018 Feb;103(2):349. PubMed PMID: 27981572; PubMed Central PMCID: PMC5474211.

12. Muir AJ, Gong L, Johnson SG, Lee MT, Williams MS, Klein TE, Caudle KE, Nelson DR; Clinical Pharmacogenetics Implementation Consortium (CPIC). Clinical

Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. Clin Pharmacol Ther. 2014

Feb;95(2):141-6. doi: 10.1038/clpt.2013.203. Epub 2013 Oct 4. PMID: 24096968; PMCID: PMC3904555.

13. Hicks JK, Bishop JR, Sangkuhl K, Müller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, LLerena A, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle KE,

Gaedigk A; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and

CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015 Aug;98(2):127-34. doi: 10.1002/cpt.147. Epub 2015 Jun 29.

Review. PubMed PMID: 25974703; PubMed Central PMCID: PMC4512908.

14. Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Müller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A, Dunnenberger HM, Klein TE, Caudle KE, Stingl

JC. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016

update. Clin Pharmacol Ther. 2017 Jul;102(1):37-44. doi: 10.1002/cpt.597. Epub 2017 Feb 13. PubMed PMID: 27997040; PubMed Central PMCID: PMC5478479.

15. Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, Wang D, Vinks AA, He Y, Swen JJ, Leeder JS, van Schaik R, Thummel KE, Klein TE, Caudle

KE, MacPhee IA. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther.

2015 Jul;98(1):19-24. doi: 0.1002/cpt.113. Epub 2015 Jun 3. PubMed PMID: 25801146; PubMed Central PMCID: PMC4481158.

Genes Alleles Genes Alleles Genes Alleles Genes Alleles Genes Alleles

CYP2B6 *12 CYP2C9 *29 DPYD c.2872A>G G6PD Mexico City RYR1 c.1597C>T

CYP2B6 *13 CYP2C9 *3 DPYD c.2933A>G G6PD Minnesota RYR1 c.1654C>T

CYP2B6 *16 CYP2C9 *30 DPYD c.295_298delTACT (*7) G6PD Montpellier RYR1 c.1840C>T

CYP2B6 *18 CYP2C9 *33 DPYD c.2983G>T (*10) G6PD Mt Sinai RYR1 c.1841G>T

CYP2B6 *19 CYP2C9 *35 DPYD c.601A>C G6PD Murcia Oristano RYR1 c.487C>T

CYP2B6 *20 CYP2C9 *37 DPYD c.61C>T G6PD Namouru RYR1 c.488G>T

CYP2B6 *22 CYP2C9 *38 DPYD c.632A>G G6PD Nankang RYR1 c.6487C>T

CYP2B6 *26 CYP2C9 *39 DPYD c.703C>T (*8) G6PD Nanning RYR1 c.6502G>A

CYP2B6 *34 CYP2C9 *42 DPYD c.868A>G G6PD Nashville RYR1 c.6617C>G

CYP2B6 *35 CYP2C9 *43 G6PD 202G>A_376A>G_1264C>G G6PD Neapolis RYR1 c.6617C>T

CYP2B6 *36 CYP2C9 *44 G6PD A202A_376G G6PD Orissa RYR1 c.7007G>A

CYP2B6 *37 CYP2C9 *45 G6PD Aachen G6PD Pawnee RYR1 c.7048G>A

CYP2B6 *38 CYP2C9 *46 G6PD Acrokorinthos G6PD Puerto Limon RYR1 c.7063C>T

CYP2B6 *6 CYP2C9 *50 G6PD Alhambra G6PD Rehevot RYR1 c.7124G>C

CYP2B6 *7 CYP2C9 *52 G6PD Ananindeua G6PD Riverside RYR1 c.7282G>A

CYP2B6 *8 CYP2C9 *55 G6PD Andalus G6PD Serres RYR1 c.7300G>A

CYP2B6 *9 CYP2C9 *6 G6PD Asahi G6PD Shenzen RYR1 c.7304G>A

CYP2C19 *10 CYP2C9 *61 G6PD Aveiro G6PD Sibari RYR1 c.7354C>T

CYP2C19 *16 CYP2D6 *2x2 G6PD Bajo Maumere G6PD Sinnai RYR1 c.7360C>T

CYP2C19 *17 CYP2D6 *2x2 G6PD Bangkok Noi G6PD Split RYR1 c.7361G>A

CYP2C19 *19 CYP2D6 *2xN G6PD Beverly Hills G6PD Surabaya RYR1 c.7372C>T

CYP2C19 *2 CYP2D6 *3 G6PD Canton G6PD Taipei‚ Chinese3 RYR1 c.7373G>A

CYP2C19 *22 CYP2D6 *44 G6PD Chatham G6PD Tomah RYR1 c.7522C>G

CYP2C19 *24 CYP2D6 *5 G6PD Chinese5 G6PD Union RYR1 c.7522C>T

CYP2C19 *25 CYP2D6 *50 G6PD Cincinnati G6PD Vancouver RYR1 c.7523G>A

CYP2C19 *26 CYP2D6 *7 G6PD Coimbra Shunde G6PD Viangchan RYR1 c.9310G>A

CYP2C19 *3 CYP2D6 *9 G6PD Cosenza IFNL3 rs12979860 variant (T) SLCO1B1 *15

CYP2C19 *35 CYP3A5 *3 G6PD G6PD A 680T_376G NUDT15 *2 SLCO1B1 *17

CYP2C19 *4 CYP3A5 *6 G6PD G6PD A968C_376G NUDT15 *3 SLCO1B1 *5

CYP2C19 *5 CYP3A5 *7 G6PD Gaohe RYR1 c.1021G>A TPMT *11

CYP2C19 *6 CYP4F2 *3 G6PD Guadalajara RYR1 c.1021G>C TPMT *14

CYP2C19 *7 DPYD c.1057C>T G6PD Harilaou RYR1 c.103T>C TPMT *15

CYP2C19 *8 DPYD c.1156G>T (*12) G6PD Hechi RYR1 c.11969G>T TPMT *2

CYP2C19 *9 DPYD c.1314T>G G6PD Lerapetra RYR1 c.1201C>T TPMT *23

CYP2C9 *13 DPYD c.1475C>T G6PD Ilesha RYR1 c.1209C>G TPMT *29

CYP2C9 *14 DPYD c.1484A>G G6PD Iowa RYR1 c.130C>T TPMT *3B

CYP2C9 *15 DPYD c.1679T>G (*13) G6PD Kaiping RYR1 c.14387A>G TPMT *3C

CYP2C9 *16 DPYD c.1775G>A G6PD KalyanKerala RYR1 c.14477C>T TPMT *4

CYP2C9 *2 DPYD c.1777G>A G6PD Lagosanto RYR1 c.14497C>T TPMT *41

CYP2C9 *23 DPYD c.1898delC (*3) G6PD Loma Linda RYR1 c.14512C>G UGT1A1 *27

CYP2C9 *24 DPYD c.1905+1G>A (*2A) G6PD Mahidol RYR1 c.14545G>A UGT1A1 *6

CYP2C9 *25 DPYD c.2021G>A G6PD Malaga RYR1 c.14693T>C VKORC1 rs9923231 variant (T)

CYP2C9 *26 DPYD c.2279C>T G6PD Mediterranean RYR1 c.1565A>C

CYP2C9 *28 DPYD c.2639G>T G6PD Metaponto RYR1 c.1589G>A

APPENDIX-1

Genessense, C/o. MedGenome Labs Ltd., 3rd Floor, Narayana Nethralaya BuildingNarayana Nethralaya City, #258/A, Bommasandra, Hosur Road, Bangalore-560 099

Phone: 1800 103 7590

Email: [email protected]

Website: www.genessense.com

To know more

about CUREGEN,

scan the QR code here

YO U R P E R S O N A L I Z E D D R U G

R E S P O N S E R E P ORT

Your personalized drug response report

scan the qr code here

Documents